Cost-Effectiveness Analysis of Herpes Zoster Vaccination in a Chinese Population: Recombinant Subunit Vaccine versus Live Attenuated Vaccine
Vaccines · 01.08.2024 · 12 (8) · 872
DOI: 10.3390/vaccines12080872 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 01.08.2024. Verfasst von Jiaqi Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, 87 Dingjiaqiao Avenue, Nanjing 210009, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Science Fund for Distinguished Young Scholars, Jiangsu Provincial Key Project of Science and Technology Plan.
Abstract (Originalsprache)
Background
Currently, the recombinant subunit vaccine and live attenuated vaccine in the prevention of herpes zoster are approved for marketing in China. This study aims to evaluate the cost-effectiveness of the recombinant subunit vaccine and the live attenuated vaccine in the Chinese population.
Methods
A decision tree–Markov analysis model was utilized to estimate expected costs and quality-adjusted life years (QALYs), comparing the lifetime cost-effectiveness of vaccination with the recombinant subunit vaccine (London, United Kingdom, Shingrix, GSK) to that of the live attenuated vaccine (Changchun, China, Ganwei, Changchun Bcht) in the Chinese population, with the primary outcome measure being the incremental cost-effectiveness ratio (ICER).
Results
In the base-case analysis, the ICERs for the recombinant subunit vaccine ranged by age from USD 3428 to USD 5743 per QALY, while the ICERs for the live attenuated vaccine ranged from USD 4017 to USD 18,254 per QALY, compared with no vaccination. Among all age groups, the category of 60 to 69 years was the optimal age for vaccination. The results were most sensitive to changes in herpes zoster incidence, vaccine efficacy, and discount rate. Even with a two-dose compliance rate of 20% for the recombinant subunit vaccine, vaccination remained cost-effective. ZVL would need to reduce costs by at least 12.2% compared to RZV to have a cost-effectiveness advantage.
Conclusions
The recombinant subunit vaccine and the live attenuated vaccine were both cost-effective in the Chinese population, but, relatively, the recombinant subunit vaccine had a greater advantage in disease prevention and cost-effectiveness in all age groups above 50 years.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, 87 Dingjiaqiao Avenue, Nanjing 210009, China.
- Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
- Key Laboratory of Environmental Medicine Engineering, Ministry of Education, School of Public Health, Southeast University, Nanjing 210009, China.
- Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200433, China.
ORCID-Profile: Hui Jin, Jingxin Li
Förderung
- National Natural Science Foundation of China
- Jiangsu Provincial Science Fund for Distinguished Young Scholars
- Jiangsu Provincial Key Project of Science and Technology Plan
Zitieren
APA
Wang, J., Jin, P., Jin, H., Wang, Q., Zhu, F., & Li, J. (2024). Cost-Effectiveness Analysis of Herpes Zoster Vaccination in a Chinese Population: Recombinant Subunit Vaccine versus Live Attenuated Vaccine. Vaccines, 12(8), 872. https://doi.org/10.3390/vaccines12080872
Vancouver
Wang J, Jin P, Jin H, Wang Q, Zhu F, Li J. Cost-Effectiveness Analysis of Herpes Zoster Vaccination in a Chinese Population: Recombinant Subunit Vaccine versus Live Attenuated Vaccine. Vaccines. 2024;12(8):872. doi:10.3390/vaccines12080872
BibTeX
@article{Wang2024,
author = {Wang, Jiaqi and Jin, Pengfei and Jin, Hui and Wang, Qiang and Zhu, Fengcai and Li, Jingxin},
title = {Cost-Effectiveness Analysis of Herpes Zoster Vaccination in a Chinese Population: Recombinant Subunit Vaccine versus Live Attenuated Vaccine},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {8},
pages = {872},
doi = {10.3390/vaccines12080872}
}
EUVIMED